3-Methyladenine (3-MA) Clinical Trials

Size	Price	Qty
50mg	USD 147
500mg	USD 370

Clinical Trials

Several clinical trials evaluate interventions across various neurological, movement, and surgical recovery conditions, including mild cognitive impairment, Alzheimer's dementia, Parkinson's disease, tremor, Tourette's syndrome, thyroid disease, and recurrent laryngeal nerve injury. Sponsored by academic institutions and regional medical centers, these early-stage Phase 1, Phase 2, and non-phased studies demonstrate varying recruitment statuses, ranging from completed to not yet recruiting or withdrawn.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07089069	NOT_YET_RECRUITING	Transcranial Direct Current Stimulation (tDCS)	Beijing Sport University	2025-07-20
NCT07706699	COMPLETED	Thyroid Disease; Recurrent Laryngeal Nerve Injury	The Second Affiliated Hospital of Kunming Medical University	2024-06-01
NCT03875326	COMPLETED	Mild Cognitive Impairment; Dementia of Alzheimer Type	University of Michigan	2019-04-01
NCT02112253	WITHDRAWN	Tourette's Syndrome	The University of Western Australia	2013-03	PHASE1; PHASE2
NCT01945567	COMPLETED	Parkinson's Disease; Tremor	The University of Western Australia	2012-08	PHASE2

(data from https://clinicaltrials.gov, updated on 2025-07-28)

Check the 3-Methyladenine (3-MA) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

3-Methyladenine acts as a selective phosphoinositide 3-kinase (PI3K) inhibitor targeting Vps34 and PI3Kγ, thereby suppressing class III PI3K signalling and blocking autophagosome formation in treated cells. By inhibiting autophagosome accumulation and regulating cellular autophagy pathways, this compound provides a valuable biochemical probe for investigating neurodegenerative pathology and neuroprotective mechanisms relevant to clinical trial conditions such as Alzheimer's disease, Parkinson's disease, and cognitive impairment.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).